Clinical evidence for oral antiplatelet therapy in acute coronary syndromes

The Lancet

Volumn 386, Issue 9990, 2015, Pages 292-302

  Wiviott, Stephen D ^a   Steg, Philippe Gabriel ^b,c,d,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSERM   (France)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; PRASUGREL; TICAGRELOR; VORAPAXAR; ADENOSINE; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SAFETY; HUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT DURATION; ANALOGS AND DERIVATIVES; DRUG COMBINATION; ORAL DRUG ADMINISTRATION; PEROPERATIVE CARE; PROCEDURES; TIME; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; ADMINISTRATION, ORAL; ASPIRIN; CORONARY ARTERY BYPASS; DRUG THERAPY, COMBINATION; HUMANS; INDIVIDUALIZED MEDICINE; INTRAOPERATIVE CARE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937629890     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60213-6     Document Type: Review

References (80)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Lancet 2 1988 349 360
2. S Yusuf, F Zhao, SR Mehta, S Chrolavicius, G Tognoni, KK Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
3. MS Sabatine, CP Cannon, CM Gibson et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
4. ZM Chen, LX Jiang, YP Chen Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
5. SR Mehta, JP Bassand, S Chrolavicius et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
6. SD Wiviott, E Braunwald, CH McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
7. MT Roe, PW Armstrong, KA Fox et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 2012 1297 1309
8. JL Mega, T Simon Pharmacology of antithrombotic agents: an exploration of oral antiplatelet and anticoagulant therapies Lancet 2015 published online March 14. http://dx/doi.org/S0140-6736(15)60243-4
9. S Elmariah, L Mauri, G Doros et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis Lancet 2014 published online Nov 16. http://dx.doi.org/10.1016/S0140-6736(14)62052-3
10. MP Bonaca, DL Bhatt, E Braunwald et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial Am Heart J 167 2014 437 444 e5
11. P Tricoci, Z Huang, C Held et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 366 2012 20 33
12. DA Morrow, E Braunwald, MP Bonaca et al. Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 2012 1404 1413
13. C Baigent, L Blackwell, R Collins et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
14. S Silberman, C Neukirch-Stoop, PG Steg Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting Am J Cardiol 95 2005 509 510
15. SR Mehta, S Yusuf, RJ Peters et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
16. G Montalescot, G Sideris, C Meuleman et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol 48 2006 931 938
17. SR Mehta, JF Tanguay, JW Eikelboom et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
18. A Schömig, FJ Neumann, H Walter et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy J Am Coll Cardiol 29 1997 28 34
19. MB Leon, DS Baim, JJ Popma et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting N Engl J Med 339 1998 1665 1671
20. ME Bertrand, HJ Rupprecht, P Urban, AH Gershlick CLASSICS Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 102 2000 624 629
21. EC Keeley, JA Boura, CL Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials Lancet 361 2003 13 20
22. PA Gurbel, KP Bliden, BL Hiatt, CM O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
23. VL Serebruany, SR Steinhubl, PB Berger, AI Malinin, DL Bhatt, EJ Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
24. L Bonello, S Armero, O Ait Mokhtar et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19∗2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
25. US Tantry, L Bonello, D Aradi et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
26. D Aradi, RF Storey, A Komócsi et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention Eur Heart J 35 2014 209 215
27. MJ Price, PB Berger, PS Teirstein et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
28. JP Collet, T Cuisset, G Rangé et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
29. D Trenk, GW Stone, M Gawaz et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
30. JL Mega, SL Close, SD Wiviott et al. Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
31. T Simon, C Verstuyft, M Mary-Krause et al. Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
32. JP Collet, JS Hulot, A Pena et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
33. JL Mega, W Hochholzer, AL Frelinger 3rd et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 2011 2221 2228
34. SS Brar, J ten Berg, R Marcucci et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 2011 1945 1954
35. SD Wiviott, EM Antman, E Braunwald Prasugrel Circulation 122 2010 394 403
36. SD Wiviott, D Trenk, AL Frelinger et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 116 2007 2923 2932
37. SD Wiviott, E Braunwald, CH McCabe et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet 371 2008 1353 1363
38. DA Morrow, SD Wiviott, HD White et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction Circulation 119 2009 2758 2764
39. EA Amsterdam, NK Wenger, RG Brindis et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 130 2014 e344 e426
40. CW Hamm, JP Bassand, S Agewall et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
41. PG Steg, SK James, D Atar et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
42. G Montalescot, SD Wiviott, E Braunwald et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
43. SD Wiviott, E Braunwald, DJ Angiolillo et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
44. SD Wiviott, HD White, EM Ohman et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial Lancet 382 2013 605 613
45. L Wallentin, RC Becker, A Budaj et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
46. PG Steg, RA Harrington, H Emanuelsson et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial Circulation 128 2013 1055 1065
47. SK James, MT Roe, CP Cannon et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial BMJ 342 2011 d3527
48. CP Cannon, RA Harrington, S James et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study Lancet 375 2010 283 293
49. D Lindholm, C Varenhorst, CP Cannon et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial Eur Heart J 35 2014 2083 2093
50. S Husted, S James, RC Becker et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial Circ Cardiovasc Qual Outcomes 5 2012 680 688
51. PG Steg, S James, RA Harrington et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
52. L Wallentin, S James, RF Storey et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
53. KW Mahaffey, DM Wojdyla, K Carroll et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 124 2011 544 554
54. RF Storey, RC Becker, RA Harrington et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes Eur Heart J 32 2011 2945 2953
55. R Mehran, U Baber, PG Steg et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (Paris): 2 year results from a prospective observational study Lancet 382 2013 1714 1722
56. L Bonello, M Laine, N Kipson et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome J Am Coll Cardiol 63 2014 872 877
57. MK Nanhwan, S Ling, M Kodakandla, S Nylander, Y Ye, Y Birnbaum Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect Arterioscler Thromb Vasc Biol 34 2014 2078 2085
58. S Bangalore, A Singh, B Toklu et al. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials Open Heart 1 2014 e000068
59. D Alexopoulos, I Xanthopoulou, V Gkizas et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
60. M Valgimigli, M Tebaldi, G Campo et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial JACC Cardiovasc Interv 5 2012 268 277
61. PG Steg, DL Bhatt, CW Hamm et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data Lancet 382 2013 1981 1992
62. DL Bhatt, GW Stone, KW Mahaffey et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
63. G Montalescot, L Bolognese, D Dudek et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes N Engl J Med 369 2013 999 1010
64. A Bellemain-Appaix, SA O'Connor, J Silvain et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis JAMA 308 2012 2507 2516
65. G Montalescot, AW van't Hof, F Lapostolle et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction N Engl J Med 371 2014 1016 1027
66. KA Fox, KF Carruthers, DR Dunbar et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study) Eur Heart J 31 2010 2755 2764
67. DL Bhatt, KA Fox, W Hacke et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
68. DL Bhatt, MD Flather, W Hacke et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial J Am Coll Cardiol 49 2007 1982 1988
69. L Mauri, DJ Kereiakes, RW Yeh et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 2014 2155 2166
70. Reuters BRIEF-AstraZeneca says heart drug study meets primary endpoint http://www.reuters.com/article/2015/01/14/idUSFWN0US01620150114 (accessed Jan 16, 2015).
71. M Lamberts, GH Gislason, JB Olesen et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention J Am Coll Cardiol 62 2013 981 989
72. R Sørensen, ML Hansen, SZ Abildstrom et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 2009 1967 1974
73. ClinicalTrials.gov. Evaluation of dual therapy with dabigatran vs. triple therapy with warfarin in patients with AF that undergo a PCIw stenting (REDUAL-PCI). https://clinicaltrials.gov/show/NCT02164864 (accessed Jan 16, 2015).
74. ClinicalTrials.gov. A study exploring two strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). https://clinicaltrials.gov/show/NCT01830543 (accessed Jan 16, 2015).
75. GY Lip, S Windecker, K Huber et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) Eur Heart J 35 2014 3155 3179
76. Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the Intracoronary Stenting and Antithrombotic Regimen - Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oral anticoagulant therapy following drug-eluting stenting (ISAR-TRIPLE) trial. J Am Coll Cardiol (in press).
77. WJ Dewilde, T Oirbans, FW Verheugt et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
78. C Held, N Asenblad, JP Bassand et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial J Am Coll Cardiol 57 2011 672 684
79. PK Smith, LT Goodnough, JH Levy et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis J Am Coll Cardiol 60 2012 388 396
80. DJ Whellan, P Tricoci, E Chen et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) J Am Coll Cardiol 63 2014 1048 1057